Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Muscle Spasticity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    84 result(s) found for: Muscle Spasticity. Displaying page 2 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2017-004497-33 Sponsor Protocol Number: Protocol_Dysport_v3__13.12.2017 Start Date*: 2018-03-06
    Sponsor Name:Copenhagen University Hospital at Hvidovre
    Full Title: Measuring effects on pain and quality of life after Dysport® injection in children with cerebral palsy
    Medical condition: Muscle pain in the extremities due to spasticity in children with cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028322 Muscle pain LLT
    20.0 100000004852 10041418 Spasticity muscle LLT
    20.1 100000004850 10021745 Infantile cerebral palsy, unspecified LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011216-38 Sponsor Protocol Number: 1.02.7001 Start Date*: 2009-09-01
    Sponsor Name:Medtronic International Trading Sarl
    Full Title: A randomized, controlled, open-label, parallel-group, multicenter study to compare the effect of Intrathecal Baclofen Therapy (ITB Therapy) versus Best Medical Treatment (BMT) on severe spasticity ...
    Medical condition: Severe spasticity in post-stroke patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) BE (Completed) DE (Completed) IT (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001777-31 Sponsor Protocol Number: IG2021370 Start Date*: 2023-05-08
    Sponsor Name:Hospital de Neurorrehabilitación Institut Guttmann
    Full Title: Pilot study on the effect of cannabinoids THC + CBD on resistant spasticity in patients with chronic spinal cord injury.
    Medical condition: Pilot study on the effect of THC+CBD cannabinoids on resistant spasticity in patients with chronic spinal cord injury.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017723-26 Sponsor Protocol Number: Y5552120142 Start Date*: 2011-04-28
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A phase III, prospective, multicentre, open label, extension study, to assess the long term safety and efficacy of repeated treatment of Dysport® intramuscular injection in the treatment of lower l...
    Medical condition: Leg Spasticity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10024132 Leg spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) IT (Completed) PT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-005197-78 Sponsor Protocol Number: 1 Start Date*: Information not available in EudraCT
    Sponsor Name:Queen's Medical Centre, Nottingham, University Hospital NHS Trust,
    Full Title: A multi-centre, randomised, parallel group, cross-over study comparing the efficacy and safety of double versus multiple injections of Botulinum Toxin type-A (Dysport®), into the gastrocnemius musc...
    Medical condition: Spasticity of the Gastrocnemius Muscle due to Cerebral Palsy
    Disease: Version SOC Term Classification Code Term Level
    8.0 10024132 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002346-37 Sponsor Protocol Number: 191622-127 Start Date*: 2014-05-21
    Sponsor Name:Allergan Limited
    Full Title: BOTOX® Treatment in Adult Patients with Upper Limb Spasticity
    Medical condition: Poststroke spasticity involving the muscles of the elbow and shoulder in adult patients
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10041416 Spasticity LLT
    17.0 100000004852 10042244 Stroke LLT
    17.0 100000004852 10048970 Arm spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003271-18 Sponsor Protocol Number: GWSP20105 Start Date*: 2021-06-07
    Sponsor Name:GW Pharma Limited
    Full Title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis
    Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-004127-40 Sponsor Protocol Number: ESPSEVMOLIN2022 Start Date*: 2023-05-03
    Sponsor Name:Dra. Nuria Gutierrez Dubón
    Full Title: Clinical trial on the effectiveness and safety of botulinum toxin type A (incobotulinumtoxin) in doses adapted to the individual needs of patients with severe spasticity
    Medical condition: brain damage oriented spasticity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000236-16 Sponsor Protocol Number: IPX056-B06-03 Start Date*: 2007-05-28
    Sponsor Name:IMPAX Laboratories, Inc.
    Full Title: A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the Pharmacokinetics and Pharmacodynamics of IPX056 in Subjects with Establis...
    Medical condition: Established Spasticity Resulting from Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-002327-42 Sponsor Protocol Number: 191622-129 Start Date*: 2014-05-21
    Sponsor Name:Allergan Limited
    Full Title: Long-term Study of BOTOX® Treatment in Adult Patients with Upper Limb Spasticity
    Medical condition: Poststroke spasticity involving the muscles of the elbow and shoulder in adult patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    20.0 100000004852 10042244 Stroke LLT
    20.0 100000004852 10048970 Arm spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002625-29 Sponsor Protocol Number: GWSP19066 Start Date*: 2020-01-14
    Sponsor Name:GW Pharma Limited
    Full Title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis
    Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-001634-18 Sponsor Protocol Number: M602011072 Start Date*: Information not available in EudraCT
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lo...
    Medical condition: Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    21.1 100000004852 10024132 Leg spasticity LLT
    20.1 100000004850 10021740 Infantile cerebral palsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001356-22 Sponsor Protocol Number: CLR_09_21 Start Date*: 2016-07-13
    Sponsor Name:Sun Pharma Advanced Research Company Ltd.
    Full Title: A PLACEBO-CONTROLLED RANDOMIZED WITHDRAWAL EVALUATION OF THE EFFICACY AND SAFETY OF BACLOFEN ER CAPSULES (GRS) IN SUBJECTS WITH SPASTICITY DUE TO MULTIPLE SCLEROSIS
    Medical condition: Spasticity due to multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-021257-39 Sponsor Protocol Number: PB-PG-0808-16319 Start Date*: 2011-07-26
    Sponsor Name:SWBH NHS Trust [...]
    1. SWBH NHS Trust
    2. Keele University
    Full Title: Is it clinically effective to treat arm flexor spasticity, with Botulinum toxin – type A (BoNTA) and physiotherapy, as soon as signs of abnormal muscle activity are observed? (A phase II study)
    Medical condition: Stroke.Spasticity.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003623-42 Sponsor Protocol Number: D-FR-10200-001 Start Date*: 2021-02-17
    Sponsor Name:Ipsen Innovation
    Full Title: An Integrated Phase I/II, Multicentre, Double-Blind, Randomised, Dysport and Placebo-Controlled, Dose-Escalation and Dose-Finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatm...
    Medical condition: Upper limb spasticity after stroke or traumatic brain injury.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019162-83 Sponsor Protocol Number: Y5252120148 Start Date*: 2011-06-07
    Sponsor Name:Ipsen Innovation
    Full Title: A phase III, multicentre, prospective, open label extension study to assess the long term safety and efficacy of repeated treatment of Dysport intramuscular injections used for the treatment of upp...
    Medical condition: Arm spasticity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10048970 Arm spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) PL (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-004100-22 Sponsor Protocol Number: OS440-3004 Start Date*: 2018-03-16
    Sponsor Name:Osmotica Pharmaceutical US LLC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Mu...
    Medical condition: Spasticity in patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000901-35 Sponsor Protocol Number: 2016-02 Start Date*: 2017-07-10
    Sponsor Name:ASISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: Riluzole for the treatment of spasticity in the traumatic chronic spinal cord injury condition: Adaptive, Multicenter, placebo-controlled, randomised, double blind trial in a Rare Disorder” RILUSCI
    Medical condition: the traumatic chronic spinal cord injury condition
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000788-30 Sponsor Protocol Number: 1.2022 Start Date*: 2023-04-13
    Sponsor Name:Uzdrowisko Kamień Pomorski S.A.
    Full Title: Evaluation of the effectiveness of Methocarbamol in the treatment of spasticity in people with spinal cord injury.
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015868-34 Sponsor Protocol Number: Y-55-52120-140 Start Date*: 2011-02-15
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY, ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULT SUBJ...
    Medical condition: Leg Spasticity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10024132 Leg spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) IT (Completed) PT (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 07:30:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA